Article Text

Download PDFPDF
Gabapentin improved sensory and motor symptoms in the restless legs syndrome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients with restless legs syndrome (RLS), is gabapentin more effective than placebo for improving sensory and motor symptoms?


13 week randomised (allocation concealed*), blinded (clinicians and patients),* placebo controlled, crossover trial.


Madrid, Spain.


24 patients who were 33–75 years of age (mean age 55 y, 67% women) and were diagnosed with idiopathic RLS (established by the International RLS Study Group). Patients with ferritin concentrations <20 μg/ml were excluded. 21 patients (88%) completed the study.


Patients were allocated to sequence 1 (gabapentin followed by placebo) or sequence 2 (placebo followed by gabapentin). Gabapentin was given at an initial dose of 600 mg/day, up to a maximum dose of 2400 mg/day. The sequences lasted 6 weeks with a 1 week washout period, and then patients …

View Full Text


  • Source of funding: Pfizer SA, Spain.

  • For correspondence: Dr D Garcia-Borreguero, Fundacion Jimenez Diaz, Madrid, Spain. dgarciaborreguero{at}

  • Abstract and commentary also appear in ACP Journal Club.

  • * See glossary.